This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2013 Jun;27(6):1416-8.

doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

C Albers, H Leischner, M Verbeek, C Yu, A L Illert, C Peschel, N von Bubnoff, J Duyster

PMID: 23392356
DOI: 10.1038/leu.2013.14

Case Reports

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

C Albers et al. Leukemia. 2013 Jun.

. 2013 Jun;27(6):1416-8.

doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.

Authors

C Albers, H Leischner, M Verbeek, C Yu, A L Illert, C Peschel, N von Bubnoff, J Duyster

PMID: 23392356
DOI: 10.1038/leu.2013.14

No abstract available

PubMed Disclaimer

Similar articles

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK, Grundler R, Peschel C, Duyster J. Kancha RK, et al. Exp Hematol. 2007 Oct;35(10):1522-6. doi: 10.1016/j.exphem.2007.07.008. Exp Hematol. 2007. PMID: 17889720
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H. Baker SD, et al. Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22. Clin Cancer Res. 2013. PMID: 23969938 Free PMC article.
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Fathi AT, Chabner BA. Fathi AT, et al. Oncologist. 2011;16(8):1162-74. doi: 10.1634/theoncologist.2011-0084. Epub 2011 Jul 17. Oncologist. 2011. PMID: 21765192 Free PMC article.
The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F, Estey E. Ostronoff F, et al. Expert Opin Investig Drugs. 2013 Dec;22(12):1659-69. doi: 10.1517/13543784.2013.842973. Epub 2013 Sep 26. Expert Opin Investig Drugs. 2013. PMID: 24070241 Review.
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR, DeAngelo DJ. Luskin MR, et al. Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.

See all similar articles

Cited by

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB, Petreaca RC. Hamid AB, et al. Cancers (Basel). 2020 Apr 9;12(4):927. doi: 10.3390/cancers12040927. Cancers (Basel). 2020. PMID: 32283832 Free PMC article. Review.
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA, Mehmood A, Jeon JY, Carmichael B, Lehman A, Orwick SJ, Truxall J, Goettl VM, Wasmuth R, Tran M, Mitchell S, Lapalombella R, Eathiraj S, Schwartz B, Stegmaier K, Baker SD, Hertlein E, Byrd JC. Elgamal OA, et al. J Hematol Oncol. 2020 Jan 28;13(1):8. doi: 10.1186/s13045-019-0821-7. J Hematol Oncol. 2020. PMID: 31992353 Free PMC article.
Potential targeting of FLT3 acute myeloid leukemia.
Ambinder AJ, Levis M. Ambinder AJ, et al. Haematologica. 2021 Mar 1;106(3):671-681. doi: 10.3324/haematol.2019.240754. Haematologica. 2021. PMID: 32703795 Free PMC article. Review.
MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B, Zhao Y, Wang X, Gong P, Ge W. Xu B, et al. Leukemia. 2017 Apr;31(4):913-921. doi: 10.1038/leu.2016.297. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27773927
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU. Lindblad O, et al. Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21. Oncogene. 2016. PMID: 26999641 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- GlyGen glycoinformatics resource
Miscellaneous
- NCI CPTAC Assay Portal